First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma

First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma
Conditions: Astrocytoma; Glioblastoma; Progressive Disease

Interventions: Biological: FT536; Procedure: Biopsy/ Intratumoral Injection/ Gross Tumor Resection; Diagnostic Test: Blood/ Cerebrospinal Fluid/ Tumor Pathology

Sponsors: Masonic Cancer Center, University of Minnesota; Fate Therapeutics

**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 4, 2026Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments